Oxford Genetics licenses CRISPR tech to power synbio push – FierceBiotech

Oxford Genetics has licensed CRISPR gene editing technology from ERS Genomics. The agreement gives the British synthetic biology service provider the right to use CRISPR technology to improve gene therapy viral vectors and develop cell lines.

Oxford, United Kingdom-based Oxford Genetics has secured the nonexclusive rights to the CRISPR intellectual property. Oxford Genetics plans to use the technology to provide genome engineering services and support its cell line development and gene therapy viral vector R&D efforts. The agreement also clears Oxford Genetics to use the CRISPR-edited cells lines in the production of biotherapeutics. And to use CRISPR to develop research tools and reagents for sale.

News of the agreement comes almost exactly three years after Horizon Discovery licensed CRISPR intellectual property from ERS Genomics for use in similar applications. The nonexclusive deal between ERS Genomics and Horizon Discoverywhich is based 70 miles away from Oxford Genetics in Cambridgegave the genomics research business the right to use CRISPR to develop research tools, kits and reagents and in other applications.

ERS Genomics was cofounded by Emmanuelle Charpentier, Ph.D., one of the key players in the story of the discovery of the CRISPR-Cas9 immune system and its role in cleaving DNA. Charpentier set up the organization to facilitate access to the CRISPR-Cas9 intellectual property she holds. The firm is on the same side of the CRISPR patent dispute as CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences. Together, the companies are appealing the U.S. patent boards ruling in the Broad Institute case.

The ruling looked at the question of whether the it was obvious to apply CRISPR to eukaryotic cells, such as the CHO and HEK293 cell lines Oxford Genetics uses in its cell line development services. But the uncertainty created by the ongoing patent dispute has not stopped Oxford Genetics from striking a deal to add CRISPR to its arsenal.

Licensing the CRISPR gene editing technology from ERS Genomics is another step on our journey to establishing the most efficient and integrated service portfolio in this sector. We are excited to be adding this technology to our existing portfolio in the synthetic biology space and supporting the rapidly expanding market for products and services that utilise genome engineering technologies, Paul Brooks, Ph.D., chief commercial officer at Oxford Genetics, said in a statement.

Read more:
Oxford Genetics licenses CRISPR tech to power synbio push - FierceBiotech

Experts say the Microbiome could overtake Genetics as the Next Big Thing – Labiotech.eu (blog)

Yesterday, a panel of experts at BioTrinity discussed the huge possibilities offered by the young microbiome field, which could soon overtake genetics.

Scientists and investors worldwide are starting to turn to the microbiome, which many believe hold the key to human health. The microorganisms that live in us and on us have shown to play a role in conditions ranging from obesity to cancer and neurodegenerative disease. I think it is a bigger deal than genetics, says Tim Spector, CEO of Map my gut, a company that offers direct-to-consumer microbiome sequencing services. But he reckons that being such a new field, still driven by small companies, very few are collecting samples of the microbiome as they should.

Back in the early days of genetics, companies would not collect DNA samples because it was too much trouble regarding ethical permissions, storage, he says. Something very similar seems to be happening with the microbiome despite the huge links with health that have been observed. The science is now there, and its obvious that anyone doing a big trial should measure how patients with different microbiome profiles respond to drugs.

Theres good evidence that efficacy and adverse effects of checkpoint inhibitors are linked to specific bacteria, agrees Mike Romanos, CEO of Microbiotica. BMScertainly believes this, as it recently signed a partnership with Enterome to study checkpoint inhibitors in the context of micrbiome-related biomarkers.

But we still have to find out how to mine such a huge potential. We need to know whats going on with the bacteria down to the strain level to fully understand their phenotype, Romanos says. With that aim, his company is building a data repository, similar to those for the human genome.

It seems that the field is rapidly growing and overcoming the challenges. The number of publications has risen exponentially in the last couple of years, says Denise Kelly from Seventure, a French VC with the first and only fund fully dedicated to microbiome companies. In a chat with her later, she explained that France is a hub with excellent microbiology research, counting with companies like MaaT Pharmaand Eligo Biosciencein addition toEnterome. France also led the European MetaHIT project, which was one of the first to sequence the microbiome, much like the Human Genome Project did before.

Kelly highlighted the main challenge at the moment is understanding the mode of action of specific organisms and the metabolites they produce. The field is in a very early stage, there are just 6 or 7 companies in clinical stage worldwide. (Indeed, when we scouted companies to include in our microbiome infographic, they seemed to be few and far between!)

For her, the next step is getting from studying correlation to identifying causality, and she knows a couple of companies that can pinpoint causality, but couldnt disclose their names. She did mention, though, the progress made with FishTaco, a system developed at the University of Washington that can discern how much each species contribute to a disease phenotype.

Furthermore, Kelly thinks that the public is more motivated than ever to look after themselves, not just regarding disease but also maintaining a healthy lifestyle. The microbiome affects every aspect of human physiology. The market is currently at 500M, but it can be much bigger if we make the right discoveries quickly, she concluded.

Images from royaltystockphoto.com, WhiteDragon /Shutterstock

Go here to read the rest:
Experts say the Microbiome could overtake Genetics as the Next Big Thing - Labiotech.eu (blog)

BRIEF-Atossa Genetics says second positive interim review on Phase 1 study of endoxifen may advance to final topical … – Reuters

UPDATE 2-Brazil inflation hits lowest in nearly 10 years in April

(Adds data, market reaction, economist's comment) By Silvio Cascione BRASILIA, May 10 Brazil's annual inflation rate fell in April to its lowest level in nearly 10 years, bolstering the view of a steep interest rate cut by the central bank at the end of this month. Consumer prices rose 4.08 percent in the 12 months through April, slightly below market forecasts for a 4.10 percent increase and compared with an increase of 4.57 percent in the year to March, the national st

Here is the original post:
BRIEF-Atossa Genetics says second positive interim review on Phase 1 study of endoxifen may advance to final topical ... - Reuters

BRIEF-JK Agri Genetics posts March-qtr profit – Reuters

Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products:

Read more here:
BRIEF-JK Agri Genetics posts March-qtr profit - Reuters

Scottish musician claims unusual world record – Independent Online

London - A man who froze his sperm more than two decades before having twins with his partner has claimed a new world record.

The Scottish musician, who did not want to be named, had his sperm frozen when he was 21, before starting chemotherapy treatment for cancer, as doctors warned him he would become infertile.

After his sperm had been kept in cold storage for 26 years and 243 days, his partner underwent in-vitro fertilisation in 2010. Its quite a big deal for a woman to take that on, he said. The couple gave birth to a girl and a boy the following year. He was 47 and his partner was 37. Now 54, he knew he held a world record, but did not want to go public.

File photo: The previous world record holder, Alex Powell, had had his sperm frozen for 23 years and the story was reported around the globe. Picture: AP

The previous world record holder, Alex Powell, had had his sperm frozen for 23 years and the story was reported around the globe. He was also about to undergo chemotherapy.

But the musician learnt he could be listed anonymously in Guinness World Records, and he agreed to speak to one newspaper to highlight how long sperm can be frozen and then used to produce healthy children. For people going through chemotherapy, they should keep hope, he told The Times.

Marco Gaudoin, director of the GCRM medical clinic where the treatment took place, said that frozen sperm could theoretically be stored indefinitely.

The Human Fertilisation and Embryology Authority claims sperm can be frozen for more than 40 years, but that not all sperm survive the process.

It has to be frozen for at least six months before it can be used for treatment, to screen the donor for infections.

The Independent

Read the original here:
Scottish musician claims unusual world record - Independent Online

One hundred women of influence: Sally Dunwoodie – Western Advocate

4 Aug 2015, 1 p.m.

The answer to the question of why so many babies are born with heart defects lies in research into the unknown and fearless funders.

Sydney embryologist Professor Sally Dunwoodie works at the frontier of genetic coding to decipher which of our 20,000 genomes are activated to help a baby's heart develop in utero. Pic supplied

ITS a curious concept, striving to fail," Sydney embryologist Professor Sally Dunwoodiesays. "It doesn't come comfortably to most people."

It's not clear that it comes easily to Dunwoodie, either, but it's a regular part of her job,working at the frontier of genetic coding to decipher which of our 20,000 genomes areactivated to help a baby's heart develop in utero.

When I ask how important failure is to her work, she laughs, and tells me about the currentresearch project into birth defects that she's running as head of embryology at the VictorChang Institute.

When the human genome was first sequenced, it took a decade and $3 million, now it can be sequenced in a week for $1600... - Professor Sally Dunwoodie

It's the biggest in Australia by a long stretch, and one of the biggest in respect of overseasresearch. Through it she hopes to find which genetic mutations trigger congenital heartdisease.

"Are we setting up to fail?" she says.

"We don't know how successful this will be. We havepredictions, that we might be able to solve 30 per cent or 40 per cent of cases, but it's in thefailure of the other 60 or 70 per cent that we will learn more, so we can know what we needto do next time."

But what constitutes failure, on a larger scale, she wonders. "Is it a total failure, even if wesolve a small percentage of cases? Or is that right, from a cost-benefit perspective? Could orshould money be spent differently?"

Part of the difficulty scientists face, in embracing what American professors of managementlike Sim Sitkin refer to as "intelligent failure", is the hurdle it places on projects, at the leadingedge of science, being granted funding.

"There is a chronic lack of funding in this country, only 10 per cent of grant applications getfunding, down from 25 per cent last year, even though they [the funding bodies] say 70 percent of applications are worthy," Dunwoodie says.

"So everyone is safe.They like you to find safe things, to have done the work basicallybefore you've got the money. That research is important, but then there is another type ofresearch which is big, interdisciplinary, it's a bit unknown, you don't really know what you'llend up with and there's a fear of failure."

And that's where Dunwoodie's interests lie.

In Australia, about eight babies are born each day with a congenital heart defect. In theUnited States, it's 40,000 a year. Worldwide, that figure is about 1 million. For the seriouscases, they need open heart surgery within 48 hours, cutting into hearts the size of a walnut.Some children require three open heart surgeries before kindergarten.

Heart defects account for 30 per cent of all birth defects, but scientists still don't know whythey happen, or who might be at risk, genetically.Until recently, money and technology has held research back.

But Dunwoodie says that haschanged, and researchers can more easily sequence all of a person's 20,000 genes in onehit, even sequencing entire genomes, which includes the genes and the DNA materialbetween them.

"When the human genome was first sequenced, it took a decade and $3 million, now it canbe sequenced in a week for $1600 ... Cheap technology means we can think bigger thanwe've ever had the possibility to do."

In 2003, at Sydney's Westmead Children's hospital, cardiac surgeon David Winlaw hit on theidea of starting a DNA bank, collecting samples from his patients and their families in thehope that one day it would be useful.

"We're talking about sifting through 3 billion pieces of information per person," Dunwoodiesays of her decision to sequence the 2000 samples in the DNA bank, and more that her ownteam of researchers have collected.

"It's just absolutely phenomenal. That kind of project though, the government fundingagencies are not going to fund. It's a fishing expedition, you don't know what you're going tofind, you need a lot of money and it's risky. But how are you ever going to get anywhereunless you push the boundaries?"

The money problem has been solved, at least in part, by donations over the past three yearsfrom Chain Reaction, a group of lycra-clad senior executives who ride 1000 kilometres eachyear raising money for children's charities.

"I get anxious about the size of the project, what people might expect ... In the businessworld, people might expect things to happen quickly, or for an 80 per cent success rate,"Dunwoodie says.

"This is a long slow business."

The Australian Financial Review/Westpac 100 Women of Influence Awards promote bold and diverse women championing change in business and society. Enter yourself orsomeone you know in one or more of the 10 categories: local/regional, board/management,innovation, culture, public policy, business enterprise, diversity, young leader, global, socialenterprise/notforprofit. Entries close August 9. For more information go to 100 Women of influence.

Here is the original post:
One hundred women of influence: Sally Dunwoodie - Western Advocate

Dartmouth-Hitchcock discontinuing infertility program leaving patients with concerns – NH1 News

LEBANON Dartmouth-Hitchcock Medical Center is discontinuing its Reproductive Endocrinology and Infertility (REI) program at the end of this month, leaving some patients with questions.

The Medical Center has evaluated its REI program over the past few months and determined that they cannot offer the quality of care that the patients need and deserve without appropriate resources, said Rick Adams, Director of External Relations for Dartmouth-Hitchcock.

News of this came as a shock for at least one patient who contacted NH1 News curious as to why the public found out before the patients did. Adams did not answer specifically why the Medical Center did not contact patients first, but did say that they were in the process of notifying patients as of 1 p.m. Tuesday, although he did not say how.

Dartmouth-Hitchcock is working towards transitioning patients to appropriate programs around the region to continue their care, Adams added.

The patient, who asked to remain anonymous, expressed concerns over how the Medical Center will ensure that her embryos, along with other patients, don't die during the transfer process to different facilities. Adams did not go into specifics regarding this question.

"While the infertility program itself will be discontinued, our Embryology and Andrology laboratory will remain available to our patients and to the programs to which they transition, as part of their continuum of care," Adams stated.

The program is coming to an end effective May 31, providing three weeks for patients to find other arrangements. Adams did not specify why the Medical Center selected this date.

Dr. Edward Merrens, Dartmouth-Hitchcock's chief clinical officer, told the Valley News the decision stemmed from difficulty in finding "the right amount of staffing" to support the work, which can involve monitoring patients seven days a week. Merrens added that the program made a profit and that financial considerations did not factor into the decision to close the program.

Adams did not answer why profits from the program were not put towards more staffing to keep the program running.

"We understand the impact this difficult decision has on our infertility patients. In the end, it is clear that we cannot sustain the program, and our belief is that ending our REI program and helping our patients find a program that can support them is in those patients best interest," Adams said.

Originally posted here:
Dartmouth-Hitchcock discontinuing infertility program leaving patients with concerns - NH1 News

Growth in Stem Cell Research – Financial Tribune

Iran is expanding investment in stem cell research and its application in various therapies, particularly for hard-to-treat diseases, through the Office of the Vice- Presidency for Science and Technology. As a result of the increase in the number of companies active in the domain of stem cells in the past three years, more than 400 products are processed in the country, indicating a multifold growth compared with the eight-year tenure of previous administration when there were fewer than 50 knowledge-based firms in total.

There are over 40 knowledgebased firms in the field of stem cell and regenerative medicine alone in Iran today, said Amir Ali Hamidiyeh, secretary of the Headquarters for Development of Stem Cell Science and Technology (HDSCST). He made the statement at a press briefing for the second National Festival and International Congress on Stem Cell Sciences and Technologies and Regenerative Medicine to be held July 13- 15 in Tehran, Mehr News Agency reports. According to the conference secretariat, 1,444 people have signed up to attend the event from across the world, including from Iraq, India, Pakistan, Jordan, Russia, Australia, Germany, China, Britain and South Korea. They all are among their countrys respected figures in centers with high academic standing.

The congress is co-sponsored by the Vice-Presidency for Science and Technology and Council on Development of Stem Cell Sciences and Technology. So far, eight stem-cell therapy products for use in hospitals have been produced at the HDSCST laboratories. Manufacturinglicenses have been granted for anadditional number, while others are on thewait list.

Prior to 2014, only 25 knowledgebased companies had applied to operate in this field, of which only one was actively producing quality stem cell products, Hamidiyeh pointed out.

But since then, over 25 workgroups have been formed in cooperation with experts in the specific sciences. Stem cells are cells that have the ability to divide and develop into many different cell types in the body during early life and growth. Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

Future of Medicine in Stem

Cells The future of medicine is interrelated with stem cell therapy and the treatment ofrefractory and incurable diseases is in this field of medicine, according to Dr. Ahmad Vosouq Dizaj, the clinical deputy of Royan Institute. Having access to engineering sciences as well as the combination of biology and medicine can play a crucial role in redressing health problems, he said. Stem cells have the ability to replace damaged cells and treat disease. They can also be used to study diseases and provide a resource for testing new medical treatments. The use of stem cells reduces the risk of viral diseases transmission and incidence of Graft Versus Host Disease (GVHD). The ability to perform organ transplants is among the benefits ofumbilical cord blood transfusion.Using stems cells is also one of thebest ways to treat blood diseases sincethe method has a success rate of 70%worldwide.

Storage of stem cells is a valuable investment. So far, 27 cord blood banks have been launched across the country. There are two types: public and private banks for stem cell storage. The former does not charge a fee for storage. But in the latter, the cost of collection and genetictesting is about $645 and the annualcharge for storage is $33, according toISNA.Iran is a leading country in biomedicalresearch. Researchers and physicians have been successfully performing bone marrow transplants during the past fewyears.Irans stem cell research is centeredat the Royan Institute for ReproductiveBiomedicine, Stem Cell Biology andTechnology, located in northern Tehran.

Original post:
Growth in Stem Cell Research - Financial Tribune

Thermo Fisher Scientific Furthers the Discussion on Disease Models in New Webinar – PR Web (press release)

David Piper, PhD Director of Research and Development, Cellular Biology, Thermo Fisher Scientific and Mark Kennedy, Ph.D. R&D Scientist at Thermo Fisher Scientific, Cell Biology ADME/Tox group

Yorba Linda, Ca (PRWEB) May 10, 2017

As part of the SyncD3 webinar series and virtual event, Thermo Fisher Scientific will discuss cutting-edge tools and topics in the fields of drug discovery & development. These tolls and topics include HCS/phenotypic assays, functional genomics & drug metabolism, 3D models/organoids, diseased models, CRISPR and stem cells.

In this webinar, attendees will gain a better understanding of where these areas intersect, the impact on drug discovery and development, as well as the future of the industry during a live panel discussion. They will learn from real field scientists and researchers who are working in the ADME/Tox and Drug Discovery fields.

The speakers for this event will be Dr. David Piper, director of research and development of Cellular Biology at Thermo Fisher Scientific, and Dr. Mark Kennedy, Scientist at Thermo Fisher Scientific, serving in the Cell Biology ADME/Tox group.

Dr. Piper earned a doctorate in neuroscience from the University of Utah. He has led teams at Thermo Fisher Scientific for more than 10 years in the development of products and services, and now as an R&D Director for the Cell Biology and Synthetic Biology businesses, he leads teams that provide molecular biology and cellular biology services.

Dr. Kennedy received his Ph.D. from Memorial University. Now in his current role at Thermo Fisher Scientific, Kennedy is part of a team that focuses on the development of new in vitro 3D cell culture models. His ongoing work focusses on the utilization of human embryonic stem cells, iPSCs and primary cells, and their application in spheroids, organoids and co-culture systems.

LabRoots will host the event May 16, 2017, beginning at 9:00 a.m. PDT, 12:00 p.m. EDT. To learn more about this event or to register for free, click here.

ABOUT THERMO FISHER SCIENTIFIC Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit http://www.thermofisher.com

ABOUT LABROOTS LabRoots is the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the worlds largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Share article on social media or email:

See the rest here:
Thermo Fisher Scientific Furthers the Discussion on Disease Models in New Webinar - PR Web (press release)

Lithium may save nerve cells after brain injury – Futurity – Futurity: Research News

A drug used to treat bipolar disorder and other forms of depression may help preserve brain function and prevent nerve cells from dying in people with a traumatic brain injury.

Scientists discovered that lithium and rapamycin, a treatment for some forms of cancer, protect nerve cells in the brain and stop the chemical glutamate from sending signals to other cells and creating further brain cell damage.

Many medications now used for those suffering with traumatic brain injury focus on treating the symptoms and stopping the pain instead of protecting any further damage from occurring, says lead author Bonnie Firestein, professor of cell biology and neuroscience at Rutgers University-New Brunswick. We wanted to find a drug that could protect the cells and keep them from dying.

Traumatic brain injury (TBI) is a major cause of death and disability in the United States with an estimated 1.7 million people sustaining an injury every year, according to the Centers for Disease Control and Prevention. About 30 percent of all deaths due to injury are due, in part, to a TBI.

TBI symptoms can include impaired thinking or memory, personality changes, and depression, as well as vision and hearing problems. The CDC reports that every day 153 people in the US die from injuries that include a TBI, with children and older adults at the highest risk.

When a TBI occurs, a violent blow to the head can result in the release of abnormally high concentrations of glutamate, which under normal circumstances is an important chemical for learning and memory. But an overproduction of glutamate, Firestein says, causes toxicity which leads to cell damage and death.

The research, reported in Scientific Reports, shows that when these two FDA-approved medications were added to damaged cell cultures in the laboratory, the glutamate was not able to send messages between nerve cellswhich stopped cell damage and death.

Further research needs to be done, in animals and humans, to determine if these drugs could help prevent brain damage and nerve cell death in humans after a traumatic brain injury.

The most common traumatic brain injury that people deal with every day is concussion which affects thousands of children each year, Firestein says. Concussions are often hard to diagnose in children because they are not as vocal, which is why it is critical to find drugs that work to prevent long-term damage.

The New Jersey Commission on Brain Injury Research funded the work. The commission is funded, in part, by traffic tickets for moving violations like speeding, using a cell phone, or driving without a license, and provides $1 to the fund from every ticket issued.

Source: Rutgers University

More:
Lithium may save nerve cells after brain injury - Futurity - Futurity: Research News